COR

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended December 31, 2005 for AmerisourceBergen Corporation (now Cencora, Inc.). The Company is a national pharmaceutical services provider operating primarily through two segments: Pharmaceutical Distribution (including ABDC and the Specialty Group) and PharMerica (Long-Term Care and Workers' Compensation). During the quarter, the Company completed a two-for-one stock split and acquired Trent Drugs (Wholesale) Ltd to expand into the Canadian market.

Key Financial Metrics

Margins: Gross profit margin improved to 3.90% of operating revenue (from 3.73% in Q4 2004). Operating income margin improved to 1.23% (from 1.10%).

Material Changes vs. Prior Period

• Revenue Growth: Operating revenue increased 11% year-over-year, driven by the Pharmaceutical Distribution segment (+11%) and PharMerica (+6%). Bulk deliveries decreased 22% due to lower demand from a major customer.
• Profitability: Net income surged 91% to $97.3 million. This was driven by a 16% increase in gross profit, largely due to strong performance under fee-for-service agreements and antitrust litigation gains ($18.0 million).
• Interest Expense: Net interest expense dropped 71% to $6.5 million due to a significant reduction in net average borrowings and a strong cash position.
• Segment Performance: Pharmaceutical Distribution operating income rose 43% to $138.9 million. Conversely, PharMerica operating income declined 21% to $18.5 million due to increased bad debt expense and costs related to Medicare Part D implementation.
• Acquisitions: The Company acquired Trent Drugs for $81.1 million (including debt assumption) to enter the Canadian market.

Guidance, Outlook, and Risks

• Outlook: Management expects annual revenue growth between 7% and 9% for fiscal 2006. Operating cash flow is projected between $500 million and $600 million. Capital expenditures are estimated at $125 million to $150 million.
• PharMerica Margin: Operating income margin for PharMerica is estimated to be between 4% and 5% for fiscal 2006, impacted by reduced compensation for Medicare Part D patients.
• Inventory Levels: Merchandise inventories rose to nearly $5.0 billion due to seasonal demand; levels are expected to normalize to $4.0–$4.5 billion by the end of fiscal 2006.
• Risks:
  • Regulatory: Potential adverse impacts from the Medicare Modernization Act (MMA) on reimbursement rates for oncology drugs and long-term care services.
  • Legal: Ongoing investigation by the New York Attorney General regarding alternate source market practices; stockholder derivative lawsuit dismissed with prejudice.
  • Operational: Risks associated with the outsourcing of IT activities to IBM and integration of new acquisitions.
• Unusual Items: The quarter included $18.0 million in gains from antitrust settlements and $8.8 million in facility consolidation and severance costs.

Investor Verification Checklist

• Inventory Turnover: Verify the sustainability of the improved inventory turnover rate (11.3x) and the expected drawdown of inventory levels in Q1 2006.
• Medicare Part D Impact: Monitor the actual financial impact of the Medicare Modernization Act on the PharMerica segment's margins in the coming quarters.
• Fee-for-Service Transition: Confirm the continued shift to fee-for-service agreements and its effect on gross margin stability versus price-dependent models.
• Legal Contingencies: Track the status of the New York Attorney General subpoena regarding alternate source purchasing.
• Debt Structure: Review the utilization of the new Canadian Credit Facility and the refinancing of the Blanco revolving credit facility due in April 2006.